A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1395-1406

  Svensson, A ^a   Chambers, C ^b   Ganemo A ^a   Mitchell, S A ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^c Decision Resources Group   (United Kingdom)

Author keywords

Eczema; Systematic review; Tacrolimus; Topical corticosteroids

Indexed keywords

ALCLOMETASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASONE BUTYRATE; CLOCORTOLONE PIVALATE; CORTICOSTEROID; DESOXIMETASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; TACROLIMUS; TRIAMCINOLONE;

ATOPIC DERMATITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; HUMAN; META ANALYSIS; OINTMENT; OUTCOME ASSESSMENT; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SKIN BURNING SENSATION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ADULT; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 79958822469     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.582483     Document Type: Review

References (50)

1. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000;4:1-191.
2. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361:151-60. (Pubitemid 36092023)
3. Flohr C, Pascoe D, Williams HC. Atopic dermatitis and the 'hygiene hypothesis': too clean to be true? Br J Dermatol 2005;152:202-16. (Pubitemid 40343589)
4. Bisgaard H, Simpson A, Palmer CN, et al. Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLoS Med 2008;5:e131.
5. van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and metaanalysis. BMJ 2009;339:b2433.
6. Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009;129:1892-908.
7. Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol 2008;121:947-54 e15.
8. Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy 2007;37:526-35. (Pubitemid 46537740)
9. Charman C, Williams HC. Epidemiology. In: Bieber T, Leung DYM, eds. Atopic Dermatitis, 1st edn. New York: Marcel Dekker, 2002:21-42.
10. Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol 1998;139:73-6. (Pubitemid 28338066)
11. Williams HC. Established corticosteroid creams should be applied only once daily in patients with atopic eczema. BMJ 2007;334:1272. (Pubitemid 46975429)
12. Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539-46. (Pubitemid 34234208)
13. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-84.
14. Hebert AA, Warken KA, Cherill R. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg 2001;20:260-7. (Pubitemid 33139093)
15. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-6. (Pubitemid 30304603)
16. Williams H. New treatments for atopic dermatitis. BMJ 2002;324:1533-4. (Pubitemid 34713124)
17. Remitz A, Reitamo S. Long-term safety of tacrolimus ointment in atopic dermatitis. Expert Opin Drug Saf 2009;8:501-6.
18. Iskedjian M, Piwko C, Shear NH, et al. Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence. Am J Clin Dermatol 2004;5:267-79. (Pubitemid 39127969)
19. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: metaanalysis of randomised controlled trials. BMJ 2005;330:516.
20. Agrup G, Lassus A, Liden S, et al. Ranking of corticosteroid ointments - an updating. Nord Med 1983;98:294-5.
21. Niedner R. Topically administered glucocorticosteroids. Part 2: Dose effect - preparations. Fortschr Med 1992;110:345.
22. Niedner R. External administration of glucocorticosteroids. Part 1: Administration guidelines - classification. Fortschr Med 1992;110:327-9.
23. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary, 57th edn. UK: BMJ Publishing Group, 2009.
24. Conde JF, Kaur M, Fleischer Jr AB, et al. Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis. Cutis 2008;81:435-41.
25. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
26. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds., Systematic Reviews in Health Care: Meta-Analysis in Context, 2nd edn. London: BMJ Publishing Group, 2008.
27. Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Invest 2006;26:235-46. (Pubitemid 43845689)
28. Doss N, Reitamo S, Dubertret L, et al. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. Br J Dermatol 2009;161:427-34.
29. Hebert AA, Koo J, Fowler J, et al. Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis. Cutis 2006;78:357-63. (Pubitemid 44952098)
30. Mandelin J, Remitz A, Virtanen H, et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol 2010;90:170-4.
31. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55. (Pubitemid 34234209)
32. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized doubleblind controlled trial. Br J Dermatol 2004;150:554-62. (Pubitemid 38446313)
33. Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, doubleblind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152:1282-9. (Pubitemid 40933430)
34. Hofman T, Cranswick N, Kuna P, et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child 2006; 91:905-10. (Pubitemid 44690203)
35. Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007;62:184-9. (Pubitemid 46090301)
36. Doss N, Kamoun MR, Dubertret L, et al. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment. Pediatr Allergy Immunol 2010;21:321-9.
37. Gradman J, Wolthers OD. Short-term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. Acta Paediatr 2007;96:1233-7. (Pubitemid 47106510)
38. Torok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis 2003;72:161-6. (Pubitemid 37229748)
39. Hung S-H, Lin Y-T, Chu C-Y, et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol 2007;98:51-6. (Pubitemid 46106158)
40. Sikder AU, Al Mamun S, Khan RM, et al. Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis - An open randomized comparative study. J Pak Assoc Dermatol 2005;15:304-12.
41. Breneman D, Fleischer Jr AB, Abramovits W, et al. Tacrolimus ointment with and without topical steroids in patients with moderate to severe atopic dermatitis. J Am Acad Dermatol 2006;54(3, Suppl 1) AB88, Abstr. P832.
42. Reitamo S. Treatment with tacrolimus ointment significantly improves the quality of life for patients with moderate to severe atopic dermatitis: results of the MOS-36 item short-form health survey. J Eur Acad Dermatol Venereol 2004;18(Suppl 2):162-3, Abstr. FC07.11.
43. Reitamo S. Quality of life improved in adults with moderate to severe atopic dermatitis treated with 0.1% tacrolimus ointment. European Academy of Dermatology and Venereology Spring Symposium, 2004.
44. Darsow U, Lubbe J, Taieb A, et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005;19:286-95. (Pubitemid 40691704)
45. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis - an emerging concept. Allergy 2009;64:276-8.
46. Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008;63:742-50.
47. Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008;159:1348-56.
48. Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat 2010;21:34-44.
49. Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? J Invest Dermatol 2003;120:932-41. (Pubitemid 36702900)
50. Schmitt J, Langan S, Williams HC. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007; 120:1389-98 (Pubitemid 350216596)